What is Micron Biomedical?
Micron Biomedical specializes in the development of dissolving microneedle-based platforms, a technology originally incubated within the laboratory of Dr. Mark Prausnitz at Georgia Tech. By utilizing microscopic structures to deliver active pharmaceutical ingredients directly into the skin, the company offers a compelling alternative to traditional hypodermic injections. This approach not only enhances patient compliance but also facilitates the distribution of vaccines and drugs in resource-constrained environments. The company's market position is bolstered by a robust network of public and private partnerships, including collaborations with the CDC, the Bill & Melinda Gates Foundation, and UNICEF, which validate the scalability and clinical utility of their delivery systems.
How much funding has Micron Biomedical raised?
Micron Biomedical has raised a total of $17M across 1 funding round:
Series A
$17M
Series A (2023): $17M with participation from Global Health Investment Fund, J2 Ventures, and LTS Lohmann Therapie-Systeme
Key Investors in Micron Biomedical
Global Health Investment Fund
A nonprofit organization dedicated to catalyzing the development of technologies that enhance human health globally, focusing on clinical diagnostics, devices, and vaccines.
J2 Ventures
A venture capital firm that provides strategic financial backing to emerging companies, focusing on high-growth potential within the technology and healthcare sectors.
LTS Lohmann Therapie-Systeme
A global pharmaceutical technology leader specializing in advanced drug delivery systems, including transdermal patches and microarray patch systems for controlled therapy release.
What's next for Micron Biomedical?
The recent infusion of capital will likely be directed toward scaling manufacturing capabilities and advancing the clinical pipeline for its microneedle vaccine delivery systems. As the company moves into a more mature lifecycle stage, the focus will shift toward regulatory milestones and the commercialization of its transdermal platforms. By leveraging the expertise of its strategic partners, Micron Biomedical is poised to disrupt the traditional pharmaceutical delivery landscape, potentially setting a new standard for global immunization efforts and chronic disease management. Future growth will likely hinge on the successful integration of these delivery systems into the portfolios of major pharmaceutical manufacturers seeking to improve patient outcomes through innovative, minimally invasive technology.
See full Micron Biomedical company page
